Department of Pathology

Daniel Jones, MD, PhD

Academy Professor

Portrait of Daniel Jones, MD, PhD

Biosketch

I am a molecular pathologist with a research focus on integrating molecular assays into cancer diagnostic and risk models. We are developing machine learning and AI-assisted tools for pathologists and as well as doing collaborations with gastroenterologists and radiologists on multiparameter AI-assisted diagnosis.  I am currently working on consensus guidelines in genomics, EHR decision support and bioinformatics with the Genomic Organization of Academic Laboratories (GOAL), the Association for Molecular Pathology (AMP) and CLSI, respectively.

Academic and Medical Appointments

2026-Present Academy Professor, Department of Pathology, The Ohio State University, Columbus, OH

2015-2025 Professor (Tenured) and Vice Chair, Department of Pathology, The Ohio State University, Columbus, OH

Education and Training

1996-1999 Post-doctoral fellowship, Harvard Medical School/Center for Blood Research, Boston, MA,

1994-1997 Residency & Fellowship, Brigham & Women's Hospital/Harvard Medical School, Boston, MA

1986-1992 Doctor of Medicine (MD), PhD, Case Western Reserve University, Cleveland, OH

1982-1986 BS, Brown University, Providence, RI

Selected Publications

Search in PubMed

  • Pan X, Tu H, Mohamed N, Avenarius M, Caruthers S, Zhao W, Jones D. FindDNAFusion: An Analytical Pipeline with Multiple Software Tools Improves Detection of Cancer-Associated Gene Fusions from Genomic DNA. J Mol Diagn. 2024 Feb;26(2):140-149. PubMed PMID: 38008285.
  • Aisner DL, Gocke CD, Jones D, Limson M, Morrissette J, Segal JP. The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology. Acad Pathol. 2023 Jul-Sep;10(3):100090. PubMed Central PMCID: PMC10424130.
  • Pan X, Patton A, Chang YS, Stevens R, Mohamed N, Hunt M, Chappell D, Hu Y, Miller C, Zhao W, Avenarius M, Jones D. Optimizing bioinformatic workflows to extract clinically usable gene expression data from targeted tumor RNA sequencing panels: comparison with total RNA-seq in cancer samples. Bioinform Adv. 2026;6(1):vbag197. PubMed Central PMCID: PMC13418193.
  • Hu Y, Jones D, Zhao W, Tozbikian G, Parwani AV, Li Z. Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma. Mod Pathol. 2025 Aug;38(8):100783. PubMed PMID: 40274067.
  • Lee JJ, Hu P, Luo K, Wang J, Neil E, Park D, Pinard R, Sawalha Y, Denlinger N, Bezerra E, Dash P, Schneider D, Krull A, Odonnell L, Alinari L, Chan WK, Jones D, Orentas RJ, de Lima M, Vasu S. Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma. iScience. 2026 Aug 21;29(8):116847. PubMed Central PMCID: PMC13400778.
  • Woyach JA, Jones D, Jurczak W, Robak T, Illés Á, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024 Sep 5;144(10):1061-1068. PubMed Central PMCID: PMC11406168.
  • Qu P, Xu K, Faraone JN, Goodarzi N, Zheng YM, Carlin C, Bednash JS, Horowitz JC, Mallampalli RK, Saif LJ, Oltz EM, Jones D, Gumina RJ, Liu SL. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell. 2024 Feb 1;187(3):585-595.e6. PubMed Central PMCID: PMC10872432.
  • Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999 Apr;10(4):463-71. PubMed PMID: 10229189.
  • Ren R, Krishna SG, Chen W, Frankel WL, Shen R, Zhao W, Avenarius MR, Garee J, Caruthers S, Jones D. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Mod Pathol. 2021 Feb;34(2):438-444. PubMed PMID: 32792597.
  • Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009 Nov 19;114(21):4675-86. PubMed Central PMCID: PMC2780304.